ETX 636
Alternative Names: ETX-636; PI3Kα targeted therapeutic - ENSEM TherapeuticsLatest Information Update: 17 Jun 2025
At a glance
- Originator ENSEM Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II HER2 negative breast cancer
Most Recent Events
- 06 Jun 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT06993844)
- 06 Jun 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Combination therapy) in USA (PO) (NCT06993844)
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)